-
2023.12.2
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
著者 Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T.
ur J Cancer. 2024 Jan;197:113469. doi: 10.1016/j.ejca.2023.113469. Epub 2023 Dec 2.
PMID: 38061214.
-
2023.12.2
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor- Mutated Advanced Non-Small-Cell Lung Cancer.
著者 Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, Yang JC.
J Clin Oncol. 2024 Mar 1;42(7):808-820. doi: 10.1200/JCO.23.02219. Epub 2023 Dec 2.
PMID: 38042525; PMCID: PMC10906563.
-
2023.11.27
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.
著者 Yamaguchi O, Kasahara N, Soda H, Imai H, Naruse I, Yamaguchi H, Itai M, Taguchi K, Uchida M, Sunaga N, Maeno T, Minato K, Tomono H, Ogawara D, Mukae H, Miura Y, Shiono A, Mouri A, Kagamu H, Kaira K.
Sci Rep. 2023 Nov 27;13(1):20848. doi: 10.1038/s41598-023-48210-5.
PMID: 38012343 Free PMC article.
-
2023.11.8
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
著者 Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators.
N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.
PMID: 37937763.
-
2023.9.19
Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
著者 Yamaguchi O, Kaira K, Imai H, Mouri A, Shiono A, Miura Y, Hashimoto K, Kobayashi K, Kagamu H.
Oncology. 2024;102(3):271-282. doi: 10.1159/000534169. Epub 2023 Sep 19.
PMID: 37725914
-
2023.8.22
Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib
著者 Kaira K, Imai H, Mouri A, Hashimoto K, Miura Y, Shiono A, Yamaguchi O, Kobayashi K, Kawasaki T, Yasuda M, Kagamu H.
Thorac Cancer. 2023 Oct;14(29):2950-2961. doi: 10.1111/1759-7714.15082. Epub 2023 Aug 22.
PMID: 37605832 Free PMC article.
-
2023.8.18
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
著者 Nishihara-Kato F, Imai H, Tsuda T, Wasamoto S, Nagai Y, Kishikawa T, Miura Y, Ono A, Yamada Y, Masubuchi K, Osaki T, Nakagawa J, Umeda Y, Minemura H, Kozu Y, Taniguchi H, Ohta H, Kaira K, Kagamu H.
Oncology. 2024;102(1):30-42. doi: 10.1159/000533604. Epub 2023 Aug 18.
PMID: 37598676
-
2023.8.29
Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
著者 Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Yoshiaki Nagai, Takayuki Kishikawa, Ken Masubuchi, Takashi Osaki, Yosuke Miura, Yukihiro Umeda, Akihiro Ono, Hiroyuki Minemura, Yutaka Yamada, Junichi Nakagawa, Yuki Kozu, Hirokazu Taniguchi, Hiromitsu Ohta, Takashi Kasai, Kyoichi Kaira, Hiroshi Kagamu.
Thorac Cancer . 2023 Sep;14(25):2567-2578. doi: 10.1111/1759-7714.15036. Epub 2023 Jul 19.
PMID: 37469246 PMCID: PMC10481141 DOI: 10.1111/1759-7714.15036
-
2023.5.8
Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma.
著者 Ito K, Yamaguchi O, Kaira K, Imai H, Kagamu H.
Lung Cancer . 2023 May:179:107193. doi: 10.1016/j.lungcan.2023.107193. Epub 2023 Apr 10.
PMID: 37058785 DOI: 10.1016/j.lungcan.2023.107193
-
2023.5.3
Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial.
著者 Fujita K, Arai R, Shoji S, Saito R, Nomura M, Hotta T, Asahina H, Kawakami M, Nakachi I, Hasegawa Y, Okafuji K, Suzuki A, Miyanaga A, Sunaga N, Nagashima H, Ikeda N, Watanabe S, Nagai Y, Furuta M, Kage H, Arai D, Fukuhara T, Nakayama M, Morita S, Kobayashi K, Hagiwara K.
Cancer Sci. 2023 Aug;114(8):3342-3351. doi: 10.1111/cas.15831. Epub 2023 May 3.
PMID: 37139543; PMCID: PMC10394136.
-
2023.3.31
A randomized controlled phase III trial protocol: perioperative pirfenidone therapy in patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis to confirm the preventative effect against postoperative acute exacerbation: the PIII-PEOPLE study (NEJ034).
著者 Sakairi Y, Yoshino I, Iwata T, Yoshida S, Kuwano K, Azuma A, Sakai S, Kobayashi K.
J Thorac Dis. 2023 Mar 31;15(3):1486-1493. doi: 10.21037/jtd-22-535. Epub 2023 Mar 6.
PMID: 37065585; PMCID: PMC10089862.
-
2023.3.2
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
著者 Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, Oizumi S, Takahashi K, Kagamu H, Tsubata Y, Seike M, Kikuchi T, Okamoto I, Satoshi M, Asahina H, Tanaka K, Sugio K, Kobayashi K.
Eur J Cancer. 2023 May;185:83-93. doi: 10.1016/j.ejca.2023.02.023. Epub 2023 Mar 2.
PMID: 36966696.
RESEARCH 研究の報告
